logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Nivolumab for hepatocellular carcinoma – adjuvant

< Back

Nivolumab for hepatocellular carcinoma – adjuvant

Drugs

Cancer and Palliative Care

August 2020


Nivolumab is in clinical development for the treatment of a primary liver cancer (hepatocellular carcinoma), which is cancer that originally develops in the liver and accounts for nine in ten primary liver cancer cases. Current treatment options commonly include surgical intervention such as liver transplants, as such there is a gap in treatment for minimally invasive pharmacological options.
Nivolumab, administered by intravenous infusion (injection into the vein), will be used as a secondary treatment for people who have already had cancerous tissue removed through surgery or other methods, but have had disease reoccurrence. Current recommended medical treatments target enzyme pathways, whereas nivolumab uses an alternative treatment pathway by targeting the immune system. Cancer cells commonly have receptor-blockers that make themselves invulnerable to the body’s immune cells, such as T-cells. Ordinarily T-cells bind to harmful, disease-causing cells or faulty cells via receptors and cause the cell to burst and die. Nivolumab works by activating T-cells, which can then kill cancer cells. Therefore, if licensed, nivolumab would offer an additional secondary treatment option for the treatment of liver cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts